Single-Agent Cabozantinib is Sufficient and Avoids Extra Toxicity in Metastatic Clear Cell Renal Cell Carcinoma Patients

Dr. Umang Swami from Huntsman Cancer Institute, University of Otah, presents in this MEDtalk a study that compared cabozantinib alone versus cabozantinib with immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma patients. The results showed no significant benefit from adding PD-1/PD-L1 inhibitors, suggesting that single-agent cabozantinib is sufficient and avoids extra toxicity.